MedCap AB AI Stock Analysis
Want to see SE:MCAP full AI Analyst Report?
MedCap AB (MCAP) AI Stock Analysis
MedCap AB
(Nasdaq OMX AB:MCAP)
The score is supported primarily by strong financial performance and favorable technical momentum. The relatively high P/E ratio and absence of dividend support weigh on the result, producing an overall score of 79.5.
MedCap AB (MCAP) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 8.30B
- Dividend Yield
- ―
- Average Volume (3M)
- 19.37K
- Price to Earnings (P/E)
- 29.6
- Beta (1Y)
- 0.43
- Revenue Growth
- 16.54%
- EPS Growth
- 39.10%
- Country
- Sweden
- Employees
- 647
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
MedCap AB Business Overview & Revenue Model
Company Description
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature b...
How the Company Makes Money
MedCap makes money primarily through the operating earnings of its consolidated portfolio companies and the value creation of those businesses over time. The core revenue engine sits in the subsidiaries/portfolio companies, which generate sales by pr...
MedCap AB Financial Statement Overview
Summary
Strong overall financial performance, supported by robust profitability, moderate leverage, rising equity, and improving cash generation. Gross-margin pressure and below-proportionate cash conversion are the main risks.
Income Statement
78PositiveBalance Sheet
86Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.32B | 2.11B | 1.81B | 1.59B | 1.11B | 916.30M |
| Gross Profit | 882.00M | 321.00M | 1.06B | 926.40M | 462.40M | 369.80M |
| EBITDA | 557.90M | 473.80M | 396.00M | 341.90M | 256.20M | 201.90M |
| Net Income | 274.40M | 219.80M | 207.40M | 172.20M | 117.60M | 96.50M |
Balance Sheet | ||||||
| Total Assets | 2.80B | 2.61B | 1.99B | 1.66B | 1.43B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 272.80M | 370.40M | 370.10M | 188.20M | 236.20M | 139.70M |
| Total Debt | 437.70M | 482.90M | 358.00M | 261.20M | 340.00M | 256.90M |
| Total Liabilities | 1.09B | 1.15B | 703.20M | 635.10M | 570.60M | 471.80M |
| Stockholders Equity | 1.71B | 1.45B | 1.28B | 1.02B | 856.30M | 696.00M |
Cash Flow | ||||||
| Free Cash Flow | 374.60M | 280.50M | 293.80M | 188.70M | 41.20M | 55.40M |
| Operating Cash Flow | 422.00M | 342.70M | 360.00M | 228.00M | 85.50M | 116.30M |
| Investing Cash Flow | -305.90M | -391.30M | -128.80M | -152.30M | -56.10M | -64.80M |
| Financing Cash Flow | -215.70M | 52.20M | -46.10M | -119.70M | 61.20M | -64.10M |
MedCap AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Neutral. The current price of 541.50 is below the 20-day moving average (MA) of 551.80, above the 50-day MA of 538.52, and above the 200-day MA of 518.53, indicating a neutral trend. The MACD of 1.84 indicates Positive momentum. The RSI at 46.24 is Neutral, neither overbought nor oversold. The STOCH value of 19.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCAP.
MedCap AB Peers Comparison
Overall Rating
SE:MCAP79.5Outperform
SE:SECT.B74Outperform
SE:GETI.B67Neutral
SE:XVIVO64Neutral
SE:VITR63Neutral
SE:SEDANA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | SEK 8.30B | 29.62 | 17.50% | ― | 16.54% | 39.10% | |
| 74Outperform | SEK 65.68B | 100.98 | 30.26% | 0.70% | 13.94% | 5.70% | |
| 67Neutral | SEK 76.26B | 26.64 | 9.13% | 1.72% | -3.90% | 37.73% | |
| 64Neutral | SEK 6.17B | 47.95 | 5.89% | ― | 17.83% | 330.94% | |
| 63Neutral | SEK 15.90B | -3.14 | -61.57% | 0.96% | -1.94% | -1223.74% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 889.07M | -24.90 | -3.88% | ― | 0.42% | 15.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:MCAP | MedCap AB | 541.50 | -2.50 | -0.46% | |
| SE:GETI.B | Getinge AB (UK) | 276.80 | 71.25 | 34.66% | |
| SE:VITR | Vitrolife AB | 115.10 | -29.81 | -20.57% | |
| SE:XVIVO | Xvivo Perfusion AB | 196.10 | 16.30 | 9.07% | |
| SE:SECT.B | Sectra AB Class B | 330.20 | 47.06 | 16.62% | |
| SE:SEDANA | Sedana Medical AB | 8.65 | -1.35 | -13.50% |
MedCap AB Corporate Events
MedCap Delivers Strong Margin Expansion and Earnings Growth in Third Quarter
MedCap AB reported strong third-quarter performance, with net sales rising 13 percent to SEK 566.7 million and EBITA surging 72 percent to SEK 154.7 million, driven partly by adjustments to contingent consideration liabilities. Even excluding items a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
